Pérez GJH, Sánchez CAR

Language: Spanish
References: 29
Page: 147-153
PDF size: 84.01 Kb.

ABSTRACT

Introduction. Elevated plasma levels of atrial natriuretic peptide (ANP) and the N-terminal fragment of the ANP prohormone (N-ANP) are associated with decreased left ventricular function and decreased long-term survival after acute myocardial infarction (AMI). Methods and results. Venous blood samples for analysis of ANP, N-ANP, and BNP were obtained on six hours after symptom onset from 56 patients with documented AMI with increased ST. We correlated independently with age, sex, diabetes, history of IM, heart failure, and levels Troponin T and BNP. Conclusions. These results suggest that plasma BNP determination provides important, independent prognostic information after AMI. Although plasma ANP appears to be a better predictor of left ventricular dysfunction, used in risk stratification after AMI and simplicity of analysis, used ingresed the pacient.

REFERENCES

1. Tan AC, van Loenhout T, Lamfers EJ, Hooghoudt TE, Kloppenborg PW, Benraad TJ. Atrial natriuretic peptide after myocardial infarction. Am Heart J 1989; 118: 490-4.

2. Jougasaki M, Yasue H, Mukoyama M, Nakao K, Takahashi K. Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. Am Heart J 1990; 119: 92-6.

3. Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E y cols. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun 1991; 180: 431-6.

4. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T y cols. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.

5. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994; 85: 334-40.

6. Kettunen RV, Leppäluoto J, Jounela A, Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J 1994; 127: 1449-55.

7. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993; 72: 255-9.

8. Omland T, Bonarjee VV, Nilsen DW, Sundsfjord JA, Lie RT, Thibault G, Dickstein K. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993; 70: 409-41.

9. Hall C, Rouleau JL, Moyé LA, de Champlain J, Bichet D, Klein M y cols. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.

10. Rouleau JL, Packer M, Moyé LA, de Champlain J, Bichet D, Klein M y cols. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91.

11. Corti R, Burnett J, Rouleau J. Vasopeptidse inhibitors. A new therapeutic concept in cariovascular disease? Circulation 2001; 104: 1856-62.

12. Omland T, Bonarjee VV, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after myocardial infarction. Am J Cardiol 1995; 76: 230-5.

13. Remes J. Neuroendocrine activation after myocardial infarction. Br Heart J 1994; 72(Suppl 3): 65-9.

14. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y y cols. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69: 1500-6.

15. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y y cols. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.

16. Arakawa N, Nakamura M, Aoki H, Moriai N, Suzuki T, Hiramori K. Prognostic value of plasma brain natriuretic peptide concentration in patients with acute myocardial infarction. Circulation 1994; 90(part 2): I-279.

17. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. On behalf of the CONSENSUS II study group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678-84.

18. Hammerer A, Polzl G, Falkensammer G. B-Type Natriuretic peptide and N-terminal pro- B type natriuretic peptide are comparably useful for disease monitoring in heart failure. Rev International Journal of Cardiology 2006: 415-7.

19. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993; 72: 1004-9.

20. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.

21. Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992; 82: 619-23.

22. Packer M, Califf M, Konstam M. Comparison of omopatrilot and enalapril in pacients with chronic heart failure: the omapatrilat versus Enalapril Randomizad Trial of Utility in Reducing Events. Circulation 2002; 106: 920-6.

23. Wayne L, Burnett C, Hartman K. Lower Rather Than Levels of Type Natriuretic peptides (NT- Pro-BNP and BNP) Predict short- Term Mortality in End- Stage Herat Failure Patients Treated UIT Neseritide. Rev JACC 2005: 835-41.

24. Jaffe A, Babulin L. Biomarkers in Acute Cardiac Disease. JACC 2006; 48: 1-11.

25. Marck R, Gary N, Espiner E. Comparison of B-Type Natriuretic Peptides for Assessment of cardiac Function and Prognosis in Stable ischemic Heart Disease. Rev JACC 2006; 47.

26. Januzzi J, Camargo A, Chen A. The N- Terminal Pro-BNP Investigation of Dysnea in the Emergency Departament (PRIDE) Study. Rev JACC 2005; 95: 948-54.

27. Dimitrios N, Georgios K, Stakos A. N-Terminal Pro- B-Type Natriuretic Peptide and Matrix Metalloproteinases in early and late left Ventricular Remodeling after Acute Myocardial Infarction. Rev JACC 2005: 949-54.

28. Rouleau J, Preffer M, Steward D. Comparison of the vasopeptidase inbibitor Omapratilat and lisinopril on exercise tolerance and morbility in patient with heart failure. IMPRESS randomizer trial. Lancet 2000; 4: 85-92.

29. Pastelón G, Valle L. De la investigación básica a los resultados clínicos. Estudios OVERTURE, ENABLE, y RENEVAL. Rev Arc Car de Mex 2003; 73: 113-5.